Finoriq research workspace
Autolus Therapeutics plc (AUTL) SEC Filings & Filing Highlights
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies. Review AUTL SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
- Company
- Autolus Therapeutics plc (AUTL)
- Ticker
- AUTL
- Market Cap
- $375.3M
- Latest Price
- $1.41
- Industry
- Biotech & Pharma
Autolus Therapeutics plc (AUTL) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Autolus Therapeutics plc (AUTL).
| Event | Form | Date |
|---|---|---|
| Ordinary ResolutionsOn June 29, 2026, Autolus Therapeutics plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholde... | 8-K5.07 | 2026-06-29 |
| Registered Number 11185179 Annual Report and financial statements for the year ended 31 Decembe...Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2025 for Autolus Therape... | 8-K8.01 | 2026-06-09 |
| autlex-991pr140526Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene... | 8-K7.01 | 2026-05-14 |
| autlex-991pr140526Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene... | 8-K2.02 | 2026-05-14 |
| Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAutolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction | 8-K7.01 | 2026-04-29 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.